Introduction: Accurate prediction of survival in patients with acute myelogenous leukemia (AML) is challenging. Therefore, we developed a predictive survival model using endocrine-related gene expression to identify an endocrine signature for accurate stratification of AML prognosis. Methods: RNA matrices and clinical data for AML were downloaded from a training dataset (Gene Expression Omnibus) and two validation datasets (the Cancer Genome Atlas and Therapeutically Applicable Research to Generate Effective Treatments). Results: In relation to the survival outcome, a risk model was constructed by incorporating seven endocrine-related genes. The model exhibited favorable predictive efficacy in estimating 5-year survival rates, as demonstrated by both the training and validation cohorts. Multivariable analysis revealed that the endocrine signature demonstrated autonomous prognostic significance in the aforementioned cohorts. Prediction accuracy for 5-year overall survival increased using a nomogram combining endocrine risk score and classical prognostic factors compared with using classical prognostic factors alone. The model predictions were confirmed using AML cell lines. Conclusion: The endocrine-related prognostic model established in this study improves AML survival prediction accuracy.

1.
Ferrara
F
,
Schiffer
CA
.
Acute myeloid leukaemia in adults
.
Lancet
.
2013
;
381
(
9865
):
484
95
.
2.
Wouters
BJ
,
Delwel
R
.
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
.
Blood
.
2016
;
127
(
1
):
42
52
.
3.
Burnett
A
,
Wetzler
M
,
Lowenberg
B
.
Therapeutic advances in acute myeloid leukemia
.
J Clin Oncol
.
2011
;
29
(
5
):
487
94
.
4.
Dohner
H
,
Estey
E
,
Grimwade
D
,
Amadori
S
,
Appelbaum
FR
,
Buchner
T
, et al
.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
.
Blood
.
2017
;
129
(
4
):
424
47
.
5.
Niederwieser
C
,
Kohlschmidt
J
,
Volinia
S
,
Whitman
SP
,
Metzeler
KH
,
Eisfeld
AK
, et al
.
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
.
Leukemia
.
2015
;
29
(
3
):
567
75
.
6.
Rucker
FG
,
Agrawal
M
,
Corbacioglu
A
,
Weber
D
,
Kapp-Schwoerer
S
,
Gaidzik
VI
, et al
.
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML study group
.
Blood
.
2019
;
134
(
19
):
1608
18
.
7.
Darbre
PD
.
Endocrine disruptors and obesity
.
Curr Obes Rep
.
2017
;
6
(
1
):
18
27
.
8.
Malespin
M
,
Nassri
A
.
Endocrine diseases and the liver: an update
.
Clin Liver Dis
.
2019
;
23
(
2
):
233
46
.
9.
Hopkins
BD
,
Goncalves
MD
,
Cantley
LC
.
Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer
.
Nat Rev Endocrinol
.
2020
;
16
(
5
):
276
83
.
10.
Ye
ZT
,
Li
YS
,
Tian
XB
,
Wei
YW
,
Yu
YH
,
Lai
KB
, et al
.
Fatty acid metabolism predicts prognosis and NK cell immunosurveillance of acute myeloid leukemia patients
.
Front Oncol
.
2022
;
12
(
12
):
1018154
.
11.
Ma
X
,
Park
Y
,
Mayne
ST
,
Wang
R
,
Sinha
R
,
Hollenbeck
AR
, et al
.
Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort
.
Am J Epidemiol
.
2010
;
171
(
3
):
312
22
.
12.
Orgel
E
,
Genkinger
JM
,
Aggarwal
D
,
Sung
LL
,
Nieder
M
,
Ladas
EJ
.
Association of body mass index and survival in pediatric leukemia: a meta-analysis
.
Am J Clin Nutr
.
2016
;
103
(
3
):
808
17
.
13.
Penning
TM
.
AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): roles in malignancy and endocrine disorders
.
Mol Cell Endocrinol
.
2019
;
489
(
489
):
82
91
.
14.
Roma
A
,
Spagnuolo
PA
.
Estrogen receptors alpha and beta in acute myeloid leukemia
.
Cancers
.
2020
;
12
(
4
):
907
.
15.
Larrue
C
,
Guiraud
N
,
Mouchel
PL
,
Dubois
M
,
Farge
T
,
Gotanègre
M
, et al
.
Adrenomedullin-CALCRL axis controls relapseinitiating drug tolerant acute myeloid leukemia cells
.
Nat Commun
.
2021
;
12
(
1
):
422
.
16.
Krivtsov
AV
,
Evans
K
,
Gadrey
JYA
,
Eschle
BK
,
Hatton
C
,
Uckelmann
HJ
, et al
.
A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia
.
Cancer Cell
.
2019
;
36
(
6
):
660
73.e11
.
17.
Brunetti
L
,
Gundry
MC
,
Sorcini
D
,
Guzman
AG
,
Huang
YH
,
Ramabadran
R
, et al
.
Mutant NPM1 maintains the leukemic state through HOX expression
.
Cancer Cell
.
2018
;
34
(
3
):
499
512.e9
.
18.
Uckelmann
HJ
,
Kim
SM
,
Wong
EM
,
Hatton
C
,
Giovinazzo
H
,
Gadrey
JY
, et al
.
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute my- eloid leukemia
.
Science
.
2020
;
367
(
6477
):
586
90
.
19.
Flamand
N
,
Picard
S
,
Lemieux
L
,
Pouliot
M
,
Bourgoin
SG
,
Borgeat
P
.
Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils
.
Br J Pharmacol
.
2006
;
149
(
4
):
385
92
.
20.
Muhammad
RN
,
Ahmed
LA
,
Abdul Salam
RM
,
Ahmed
KA
,
Attia
AS
.
Crosstalk among NLRP3 inflammasome, ETBR signaling, and miRNAs in stress-induced depression-like behavior: a modulatory role for SGLT2 inhibitors
.
Neurotherapeutics
.
2021
;
18
(
4
):
2664
81
.
21.
Pawluczyk
IZ
,
Patel
SR
,
Harris
KP
.
Perindoprilat modulates the activity of lipoprotein receptor-related protein in human mesangial cells
.
J Biol Chem
.
2008
;
283
(
8
):
4588
94
.
22.
Ye
H
,
Adane
B
,
Khan
N
,
Alexeev
E
,
Nusbacher
N
,
Minhajuddin
M
, et al
.
Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells
.
Cancer Cell
.
2018
;
34
(
4
):
659
73.e6
.
23.
Pruitt
KD
,
Tatusova
T
,
Maglott
DR
.
NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins
.
Nucleic Acids Res
.
2007
;
35
(
Database issue
):
D61
5
.
24.
Lai
Y
,
OuYang
G
,
Sheng
L
,
Zhang
Y
,
Lai
B
,
Zhou
M
.
Novel prognostic genes and subclasses of acute myeloid leukemia revealed by survival analysis of gene expression data
.
BMC Med Genomics
.
2021
;
14
(
1
):
39
.
25.
Hassan
JJ
,
Lieske
A
,
Dörpmund
N
,
Klatt
D
,
Hoffmann
D
,
Kleppa
MJ
, et al
.
A multiplex CRISPR-screen identifies PLA2G4A as prognostic marker and druggable target for HOXA9 and MEIS1 dependent AML
.
Int J Mol Sci
.
2021
;
22
(
17
):
9411
,
26.
Bai
HS
,
Zhou
MX
,
Zeng
M
,
Han
LY
.
PLA2G4A is a potential biomarker predicting shorter overall survival in patients with non-M3/NPM1 wildtype acute myeloid leukemia
.
DNA Cell Biol
.
2020
;
39
(
4
):
700
8
.
27.
Lai
WJ
,
Chen
F
,
Shu
LL
,
Yang
XM
,
Yuan
JM
,
Xu
JB
, et al
.
Pivotal role of cytosolic phospholipase PLA2G4A in the pathogenesis of FLT3-ITD-mutated acute myeloid leukemia
.
Genes Dis
.
2023
;
10
(
1
):
22
5
.
28.
Bai
H
,
Zhou
M
,
Zeng
M
,
Han
L
.
PLA2G4A is a potential biomarker predicting shorter overall survival in patients with non-M3/NPM1 wildtype acute myeloid leukemia
.
DNA Cell Biol
.
2020
;
39
(
4
):
700
8
.
29.
Rivera-Gonzalez
OJ
,
Kasztan
M
,
Johnston
JG
,
Hyndman
KA
,
Speed
JS
.
Loss of endothelin type B receptor function improves insulin sensitivity in rats
.
Can J Physiol Pharmacol
.
2020
;
98
(
9
):
604
10
.
30.
Vasaikar
S
,
Tsipras
G
,
Landázuri
N
,
Costa
H
,
Wilhelmi
V
,
Scicluna
P
, et al
.
Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target
.
BMC Cancer
.
2018
;
18
(
1
):
154
.
31.
Hsiao
PC
,
Liu
M
,
Chen
L
,
Tsai
CY
,
Wang
Y
,
Chen
J
, et al
.
Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan
.
Chin J Physiol
.
2008
;
51
(
1
):
5127
31
.
32.
Chae
YK
,
Dimou
A
,
Pierce
S
,
Kantarjian
H
,
Andreeff
M
.
The effect of calcium channel blockers on the outcome of acute myeloid leukemia
.
Leuk Lymphoma
.
2014
;
55
(
12
):
2822
9
.
33.
Chisi
JE
,
Briscoe
CV
,
Ezan
E
,
Genet
R
,
Riches
AC
,
Wdzieczak-Bakala
J
.
Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation
.
Br J Haematol
.
2000
;
109
(
3
):
563
70
.
34.
Jokubaitis
VJ
,
Sinka
L
,
Driessen
R
,
Whitty
G
,
Haylock
DN
,
Bertoncello
I
, et al
.
Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues
.
Blood
.
2008
;
111
(
8
):
4055
63
.
35.
Sinka
L
,
Biasch
K
,
Khazaal
I
,
Péault
B
,
Tavian
M
.
Angiotensin-converting enzyme (CD143) specifies emerging lympho-hematopoietic progenitors in the human embryo
.
Blood
.
2012
;
119
(
16
):
3712
23
.
36.
Aksu
S
,
Beyazit
Y
,
Haznedaroglu
IC
,
Canpinar
H
,
Kekilli
M
,
Uner
A
, et al
.
Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML
.
Leuk Lymphoma
.
2006
;
47
(
5
):
891
6
.
37.
Beyazit
Y
,
Aksu
S
,
Haznedaroglu
IC
,
Kekilli
M
,
Misirlioglu
M
,
Tuncer
S
, et al
.
Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia
.
J Natl Med Assoc
.
2007
;
99
(
1
):
57
63
.
38.
De la Iglesia Iñigo
S
,
López-Jorge
CE
,
Gómez-Casares
MT
,
Lemes Castellano
A
,
Martín Cabrera
P
,
López Brito
J
, et al
.
Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents
.
Leuk Res
.
2009
;
33
(
6
):
810
6
.
39.
Itoh
M
,
Sasaki
S
,
Tohda
SJ
.
Renin-angiotensin system inhibitors suppress the growth of leukemia cells
.
Anticancer Res
.
2024
;
44
(
3
):
1183
92
.
40.
Chae
YK
,
Dimou
A
,
Pierce
S
,
Kantarjian
H
,
Andreeff
M
.
The effect of calcium channel blockers on the outcome of acute myeloid leukemia
.
Leuk Lymphoma
.
2014
;
55
(
12
):
2822
9
.
41.
Yuan
Y
,
Wang
Q
,
Ma
S
,
Xu
L
,
Liu
M
,
Han
B
, et al
.
lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/β-catenin signaling pathway
.
Am J Transl Res
.
2019
;
11
:
7104
14
.
42.
Nguyen
C
,
Gluxam
T
,
Schlerka
A
,
Bauer
K
,
Grandits
AM
,
Hackl
H
, et al
.
SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness
.
Sci Rep
.
2019
;
9
(
1
):
9139
.
43.
Zhang
R
,
Huo
CH
.
Long noncoding RNA SOCS2 promotes leukemogenesis in FLT3-itd+ acute myeloid leukemia through miRNA-221
.
Onco Targets Ther
.
2020
;
5
(
13
):
2925
34
.
44.
Kim
JH
,
Lee
MJ
,
Yu
GR
,
Kim
SW
,
Jang
KY
,
Yu
HC
et al
.
Alterations in the p53-SOCS2 axis contribute to tumor growth in colon cancer
.
Exp Mol Med
.
2018
;
50
(
4
):
1
10
.
45.
Grandits
AM
,
Wieser
R
.
Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A
.
Exp Hematol
.
2021
;
99
:
991
11
.
46.
Tabe
Y
,
Tafuri
A
,
Sekihara
K
,
Yang
H
,
Konopleva
M
.
Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia
.
Expert Opin Ther Targets
.
2017
;
21
(
7
):
705
14
.
47.
Yan
F
,
Shen
N
,
Pang
JX
,
Zhang
YW
,
Rao
EY
,
Bode
AM
, et al
.
Fatty acid binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells
.
Leukemia
.
2017
;
31
(
6
):
1434
42
.
48.
Yan
F
,
Shen
N
,
Pang
J
,
Zhao
N
,
Zhang
Y
,
Bode
AM
, et al
.
A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target
.
Leukemia
.
2018
;
32
:
32865
873
.
You do not currently have access to this content.